Arena Pharma (ARNA) Misses Q3 EPS by 14c

Arena Pharma (NASDAQ: ARNA) reported Q3 EPS of ($1.46), $0.14 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $2.06 million.

"Arena continues to have a strong 2019 and we remain highly focused on achieving several key clinical and regulatory goals. This year we have initiated multiple important trials, including the etrasimod Phase 3 ELEVATE UC 52 trial, the olorinab Phase 2 CAPTIVATE trial, and the etrasimod Phase 2 ADVISE trial. We remain on track to initiate the etrasimod Ph 2/3 program in Crohn\'s disease and to file an IND for APD418 this year," said Amit D. Munshi, President and CEO of Arena. "We look forward to delivering on our exciting milestones and will continue to be bold and creative as we scale our enterprise to advance our pipeline."

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Humana soars, Alignment Healthcare sinks on Medicare rating changes
• Piper Sandler Upgrades Jack Henry (JKHY) to Overweight
• Kotak Upgrades Thermax Ltd (TMX:IN) to Buy (1)